{"id":44695,"date":"2022-06-04T00:01:28","date_gmt":"2022-06-03T22:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biomarkers-may-predict-better-immunotherapy-treatment-outcomes-for-certain-patients-with-pancreatic-cancer\/"},"modified":"2022-06-04T00:01:28","modified_gmt":"2022-06-03T22:01:28","slug":"biomarkers-may-predict-better-immunotherapy-treatment-outcomes-for-certain-patients-with-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biomarkers-may-predict-better-immunotherapy-treatment-outcomes-for-certain-patients-with-pancreatic-cancer\/","title":{"rendered":"Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer"},"content":{"rendered":"
\n

\nFindings from the Parker Institute for Cancer Immunotherapy (PICI) and its collaborative network of researchers, including from the University of Pennsylvania, presented at 2022 ASCO Annual Meeting and published in Nature Medicine<\/i>\n<\/p>\n

\nNew data from the PRINCE clinical trial, co-funded by PICI<\/i>, Bristol Myers Squibb and the Cancer Research Institute in collaboration with Apexigen, could aid patient selection in future chemoimmunotherapy studies<\/i>\n<\/p>\n

\nPancreatic cancer remains one of the most <\/i>crucial challenges in oncology and is predicted to become the No. 2 cause of cancer death in the U.S. by 2040<\/i>\n<\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–#ASCO22<\/a>–Researchers have identified certain patients with pancreatic cancer who may be more likely to benefit from combination treatment regimens consisting of immunotherapy and chemotherapy. These new data, stemming from a long-term collaboration between academia, biotech, pharma and nonprofits within the Parker Institute for Cancer Immunotherapy<\/a> (PICI) network, were shared with the medical community at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<\/a> in Chicago today. The comprehensive clinical and immunologic findings of the Phase II clinical trial, known as the PRINCE study, were published simultaneously in the peer-reviewed journal Nature Medicine<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nApproximately 60,000 people are diagnosed with pancreatic cancer every year in the U.S., and the prognosis is typically poor. For the subset of patients diagnosed with advanced metastatic pancreatic ductal adenocarcinoma (mPDAC), the disease studied in PRINCE, the five-year survival rate is less than 5%1<\/sup>.\n<\/p>\n

\nThe findings are part of a recent analysis of data from the PRINCE trial, sponsored by PICI, and designed on the basis of decades of research by lead Principal Investigator Robert Vonderheide, M.D., D.Phil., and others at the University of Pennsylvania. The trial involved seven PICI network institutions, and uncovered various predictive biomarkers associated with longer overall survival for a subset of mPDAC patients.\n<\/p>\n

\nThe PRINCE trial evaluated the combination of standard-of-care chemotherapy (gemcitabine + nab-paclitaxel) and nivolumab, a PD-1 inhibitor, and\/or sotigalimab, an experimental antibody that is an agonist of the CD40 protein. As part of exploratory analyses, PICI researchers discovered distinct biosignatures associated with survival for the nivolumab-chemotherapy and sotigalimab-chemotherapy treatment arms, which reflect each immunotherapy’s distinct mechanisms of action. Few biomarkers predicted survival in patients receiving the sotigalimab-nivolumab-chemotherapy regimen.\n<\/p>\n

\n\u201cWhile the data from the trial suggest that these treatment regimens may not be appropriate for all PDAC patients, we uncovered various predictive biomarkers from the circulation and tumor that may correlate with longer survival and warrant further study,\u201d said Lacey Padron, Ph.D., Vice President, Informatics at PICI and lead study author. \u201cWe are encouraged by the data and believe chemoimmunotherapy combinations may improve outcomes for some patients with metastatic PDAC. Following up on these results, the scientific community can work to better understand who is most likely to benefit and why.\u201d\n<\/p>\n

\nThe PRINCE trial<\/a> was conducted in collaboration with:\n<\/p>\n